Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0264 | 1 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0264 | 1 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0264 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0264 | 1 | 1 |
Brugia malayi | brahma associated protein 60 kDa | 0.0264 | 1 | 1 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0094 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0264 | 1 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0264 | 1 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0264 | 1 | 0.5 |
Onchocerca volvulus | 0.0264 | 1 | 1 | |
Schistosoma mansoni | glutaminyl cyclase (M28 family) | 0.0129 | 0.2059 | 0.2059 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0264 | 1 | 1 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0094 | 0 | 0.5 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0094 | 0 | 0.5 |
Echinococcus multilocularis | glutaminyl peptide cyclotransferase | 0.0129 | 0.2059 | 0.2059 |
Schistosoma mansoni | brg-1 associated factor | 0.0264 | 1 | 1 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0264 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0264 | 1 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0264 | 1 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0264 | 1 | 1 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0094 | 0 | 0.5 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0094 | 0 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0264 | 1 | 1 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0264 | 1 | 1 |
Echinococcus granulosus | glutaminyl peptide cyclotransferase | 0.0129 | 0.2059 | 0.2059 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0264 | 1 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0264 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0264 | 1 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0094 | 0 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0264 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0094 | 0 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0264 | 1 | 1 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0264 | 1 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0094 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0129 | 0.2059 | 0.2059 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.0094 | 0 | 0.5 |
Brugia malayi | Peptidase family M28 containing protein | 0.0129 | 0.2059 | 0.2059 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0264 | 1 | 1 |
Onchocerca volvulus | Glutaminyl cyclase homolog | 0.0129 | 0.2059 | 0.2059 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.